<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434745</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL073980</org_study_id>
    <secondary_id>R01HL073980</secondary_id>
    <nct_id>NCT01434745</nct_id>
  </id_info>
  <brief_title>SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation</brief_title>
  <official_title>Smith-Lemli Opitz Syndrome: A Clinical Investigation of the Effect of Simvastatin in Patients Receiving Cholesterol Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if simvastatin improves development and behavior in
      patients with Smith Lemli-Opitz syndrome (SLOS) receiving dietary cholesterol
      supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with SLOS receiving dietary cholesterol supplementation are given simvastatin, a
      drug that decreases the activity/expression of HMG-CoA reductase, an enzyme that controls the
      first step of the cholesterol synthesis pathway, reduces the accumulation of toxic
      7-dehydrocholesterol (immediate metabolic precursor of cholesterol) and improve
      neurocognitive and behavioral outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrollment (only one subject enrolled)
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development Quotient (DQ)</measure>
    <time_frame>through study completion, an average of 2 per year</time_frame>
    <description>neurocognitive assessment measured with Mullen Scales of Learning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole Body Cholesterol Pool Size, Synthesis &amp; Absorption Using Stable Isotope Testing</measure>
    <time_frame>end of treatment, an average of 1 per year</time_frame>
    <description>administration of cholesterol and water labeled with stable isotope followed by measurement overtime in blood concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Marker of Sterol Metabolism</measure>
    <time_frame>through study completion, an average of 2 per year</time_frame>
    <description>Blood cholesterol to 7-dehydrocholesterol ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADC</measure>
    <time_frame>end of treatment, an average of 1 per year</time_frame>
    <description>Apparent diffusion coefficient measured by brain diffusion tensor imaging (DTI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MVA</measure>
    <time_frame>through study completion, an average of 2 per year</time_frame>
    <description>urinary mevalonate excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRS Lipids</measure>
    <time_frame>end of treatment, an average of 1 per year</time_frame>
    <description>Brain magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FA</measure>
    <time_frame>end of treatment, an average of 1 per year</time_frame>
    <description>Fractional anisotropy as measured by brain diffusion tensor imaging (DTI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Smith-Lemli-Opitz Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg body weight/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor, Flolipid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactose</intervention_name>
    <description>Lactose will be administered in a capsule formula.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 1 years old

          -  Subject has confirmed diagnosis of Smith-Lemli-Opitz Syndrome

          -  Subject is currently receiving cholesterol supplementation

        Exclusion Criteria:

          -  Subjects too ill to travel to the study site

          -  Subjects who are unable to safely undergo study procedures

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Baptiste Roullet, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <results_first_submitted>September 12, 2019</results_first_submitted>
  <results_first_submitted_qc>September 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2019</results_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jean-Baptiste Roullet</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>SLOS</keyword>
  <keyword>Cholesterol Supplementation</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smith-Lemli-Opitz Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only one participant enrolled</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo - Lactose</title>
          <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
        </group>
        <group group_id="P2">
          <title>Simvastatin</title>
          <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analyses were not completed and will never be completed due to insufficient funding</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo - Lactose</title>
          <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
        </group>
        <group group_id="B2">
          <title>Simvastatin</title>
          <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Development Quotient (DQ)</title>
        <description>neurocognitive assessment measured with Mullen Scales of Learning</description>
        <time_frame>through study completion, an average of 2 per year</time_frame>
        <population>No funding</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Lactose</title>
            <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Development Quotient (DQ)</title>
          <description>neurocognitive assessment measured with Mullen Scales of Learning</description>
          <population>No funding</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Whole Body Cholesterol Pool Size, Synthesis &amp; Absorption Using Stable Isotope Testing</title>
        <description>administration of cholesterol and water labeled with stable isotope followed by measurement overtime in blood concentrations</description>
        <time_frame>end of treatment, an average of 1 per year</time_frame>
        <population>Analyses were not completed and will never be completed due to insufficient funding</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Lactose</title>
            <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Body Cholesterol Pool Size, Synthesis &amp; Absorption Using Stable Isotope Testing</title>
          <description>administration of cholesterol and water labeled with stable isotope followed by measurement overtime in blood concentrations</description>
          <population>Analyses were not completed and will never be completed due to insufficient funding</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Marker of Sterol Metabolism</title>
        <description>Blood cholesterol to 7-dehydrocholesterol ratio</description>
        <time_frame>through study completion, an average of 2 per year</time_frame>
        <population>Analyses were not completed and will never be completed due to insufficient funding</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Lactose</title>
            <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Marker of Sterol Metabolism</title>
          <description>Blood cholesterol to 7-dehydrocholesterol ratio</description>
          <population>Analyses were not completed and will never be completed due to insufficient funding</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADC</title>
        <description>Apparent diffusion coefficient measured by brain diffusion tensor imaging (DTI)</description>
        <time_frame>end of treatment, an average of 1 per year</time_frame>
        <population>Analyses were not completed and will never be completed due to insufficient funding</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Lactose</title>
            <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>ADC</title>
          <description>Apparent diffusion coefficient measured by brain diffusion tensor imaging (DTI)</description>
          <population>Analyses were not completed and will never be completed due to insufficient funding</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MVA</title>
        <description>urinary mevalonate excretion</description>
        <time_frame>through study completion, an average of 2 per year</time_frame>
        <population>Analyses were not completed and will never be completed due to insufficient funding</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Lactose</title>
            <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>MVA</title>
          <description>urinary mevalonate excretion</description>
          <population>Analyses were not completed and will never be completed due to insufficient funding</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRS Lipids</title>
        <description>Brain magnetic resonance spectroscopy</description>
        <time_frame>end of treatment, an average of 1 per year</time_frame>
        <population>Analyses were not completed and will never be completed due to insufficient funding</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Lactose</title>
            <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>MRS Lipids</title>
          <description>Brain magnetic resonance spectroscopy</description>
          <population>Analyses were not completed and will never be completed due to insufficient funding</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FA</title>
        <description>Fractional anisotropy as measured by brain diffusion tensor imaging (DTI)</description>
        <time_frame>end of treatment, an average of 1 per year</time_frame>
        <population>Analyses were not completed and will never be completed due to insufficient funding</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Lactose</title>
            <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>FA</title>
          <description>Fractional anisotropy as measured by brain diffusion tensor imaging (DTI)</description>
          <population>Analyses were not completed and will never be completed due to insufficient funding</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Lactose</title>
          <description>Placebo-Lactose
Lactose: Lactose will be administered in a capsule formula.</description>
        </group>
        <group group_id="E2">
          <title>Simvastatin</title>
          <description>0.5 mg/kg body weight/day
Simvastatin: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analyses were not completed and will never be completed due to insufficient funding</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. jean-Baptiste Roullet</name_or_title>
      <organization>Washington State University</organization>
      <phone>5093587666</phone>
      <email>j.roullet@wsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

